JO
KAPA

John Overdeck’s Kairos Pharma KAPA Stock Holding History

John Overdeck’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,543
Closed -$22.1K – 5517
2026
Q1 		$22.1K Sell
39,543
-54,465
-58% -$36.5K ﹤0.01% 4506
2025
Q4 		$66.7K Buy
94,008
+48,219
+105% +$45.1K ﹤0.01% 3897
2025
Q3 		$53.6K Buy
+45,789
New +$52.3K ﹤0.01% 3540

Other funds holding KAPA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's KAPA Position: Q2 2026 in Review

John Overdeck sold out of Kairos Pharma (KAPA) in Q2 2026, closing a stake of 39,543 shares — an estimated $22.1K sold.

John Overdeck first reported a position in KAPA in Q3 2025 and held it in 3 quarters. The position peaked at $66.7K in Q4 2025. 14 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • John Overdeck reported no remaining Kairos Pharma position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 39,543 Kairos Pharma shares in Q2 2026, an estimated $22.1K.
  • John Overdeck first reported a position in Kairos Pharma in Q3 2025 and held it in 3 quarters.
  • John Overdeck's Kairos Pharma position peaked at $66.7K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.